Library›Substances and pharmacology›Enzyme Inhibition Kinetics and Molecular Transporters

Enzyme Inhibition Kinetics and Molecular Transporters

Enzyme Inhibition Kinetics and Molecular Transporters establishes the physical-chemical laws, mathematical models, and structural biology governing how inhibitors suppress catalytic enzymes and how transporter proteins govern neurotransmitter clearance. From Michaelis-Menten dynamics to the serine hydrolase superfamily and solute carrier (SLC) transporters, this article provides the foundational framework connecting cannabinoid enzymes, monoamine oxidases, and cholinesterases.

Mathematical models of enzyme inhibition

Enzyme velocity ($V$) as a function of substrate concentration ($[S]$) follows the classical Michaelis-Menten equation:

: <code>V = (Vmax · [S]) / (Km + [S])</code>

where $V_{max}$ is the maximum catalytic rate at substrate saturation, and $K_m$ (the Michaelis constant) represents the substrate concentration at which velocity is half-maximal ($V_{max}/2$), inversely reflecting substrate affinity.

Inhibitors perturb this relationship through distinct kinetic modes, diagnosable via double-reciprocal Lineweaver-Burk plots ($1/V$ versus $1/[S]$):

{| class="wikitable"

! Inhibition mode !! Binding target !! Effect on Vmax !! Effect on Km !! Lineweaver-Burk intersection !! Biological example

| Competitive || Free enzyme active site ($E$) || Unchanged || Increased (Lower affinity) || Intersects at y-axis ($1/V_{max}$) || Galantamine at AChE; Macamides at FAAH

| Non-Competitive || Allosteric site on both $E$ and $ES$ equally || Decreased || Unchanged || Intersects at x-axis ($-1/K_m$) || Heavy metals; certain flavonoid allosteric modulators

| Uncompetitive || Only the enzyme-substrate complex ($ES$) || Decreased || Decreased || Parallel lines (slope unchanged) || Lithium at inositol monophosphatase

| Mixed || Allosteric site; unequal affinity for $E$ vs $ES$ || Decreased || Increased or Decreased || Intersects to the left of y-axis || Pristimerin at MAGL

| Irreversible (Suicide) || Active catalytic residues (Covalent) || Permanently lowered || Apparent shift || Progressive time-dependent loss || Organophosphates at AChE; URB597 at FAAH

1. Competitive inhibition dynamics

Because competitive inhibitors bind reversibly to the exact catalytic pocket used by the substrate, excess substrate can completely displace the inhibitor:

At infinite substrate concentration, maximal velocity ($V_{max}$) is fully achieved.
This property underpins why Reversible Inhibitors of MAO-A (RIMAs) avoid the tyramine "cheese crisis"—dietary tyramine surges displace the inhibitor and preserve clearance.

2. Irreversible and mechanism-based suicide inhibition

Suicide inhibitors are initially recognized as substrates by the enzyme.
The catalytic machinery converts the inhibitor into a chemically reactive species that forms a permanent covalent bond with active site amino acids, destroying the enzyme.
Restoring catalytic activity requires de novo protein synthesis, explaining why the physiological effects of compounds like irreversible MAOIs (phenelzine) or mechanism-based CYP3A4 inhibitors (grapefruit furanocoumarins) outlast the presence of the drug in plasma by days or weeks.

The Serine Hydrolase Superfamily

A remarkable unity across pharmacology is that FAAH, MAGL, Acetylcholinesterase (AChE), and Carboxylesterases all belong to the broader serine hydrolase superfamily. They share a common catalytic mechanism:

<code>

[ Free Enzyme: Enz-CH2-OH (Serine) ] + [ Substrate: R-CO-X ]

│

▼ Nucleophilic Attack by Catalytic Serine

[ Tetrahedral Intermediate 1 ]

│

▼ Expulsion of Leaving Group (X-H)

[ Covalent Acyl-Enzyme Intermediate: Enz-CH2-O-CO-R ]

│

▼ Nucleophilic Attack by Water (H2O)

[ Tetrahedral Intermediate 2 ]

│

▼ Release of Carboxylic Acid (R-COOH)

[ Regenerated Free Enzyme: Enz-CH2-OH ]

</code>

1. The universal catalytic serine nucleophile

Whether organized as a canonical Ser-His-Asp triad (AChE, MAGL) or an amidase Ser-Ser-Lys triad (FAAH), the catalytic core relies on an activated serine hydroxyl ($-\text{CH}_2\text{-OH}$) acting as a powerful nucleophile.
The serine attacks the carbonyl carbon of esters, amides, or thioesters, forming a transient covalent acyl-enzyme intermediate.
Water attacks the intermediate (deacylation), releasing the reaction product and regenerating the active enzyme.

2. Cross-reactivity and target vulnerability

Because these enzymes share this identical catalytic nucleophile, electrophilic chemical classes—specifically carbamates, ureas, and organophosphates—can cross-react across multiple family members.
If a synthetic drug molecule is designed with excessive electrophilic reactivity, it will non-selectively carbamylate or phosphorylate off-target serine hydrolases throughout the brain. This exact mechanism produced the 2016 BIA 10-2474 trial tragedy, where an unselective candidate inhibited FAAH alongside ABHD6, ABHD11, and neuropathy target esterase (PNPLA6), destroying neuronal lipid homeostasis.

Molecular reuptake transporters

Where enzymes clear neurotransmitters by chemical destruction, molecular transporters clear neurotransmitters by physically pumping them across cellular membranes against steep concentration gradients:

<code>

[ MOLECULAR TRANSPORTERS ]

│

┌─────────────────────────┼─────────────────────────┐

▼ ▼ ▼

[ SLC6 Plasma Transporters ] [ SLC18 Vesicular (VMAT2) ] [ Intracellular Chaperones ]

• SERT (Serotonin / SSRIs) • Pumps monoamines into • FABP5 / FABP7 (Anandamide)

• DAT (Dopamine / Stimulants) presynaptic vesicles • Chaperones lipids through

• NET (Norepinephrine) • Powered by H⁺-ATPase cytosol to FAAH / MAGL

• GAT1 (GABA / Anticonvulsants) • Reserpine target

</code>

1. The Solute Carrier 6 (SLC6) superfamily

The plasma membrane monoamine transporters—SERT (SLC6A4), DAT (SLC6A3), and NET (SLC6A2)—are $Na^+/Cl^-$-coupled symporters.
They utilize the steep electrochemical gradient generated by the $Na^+/K^+$-ATPase pump (two sodium ions and one chloride ion transported inward per neurotransmitter molecule) to drive high-affinity reuptake from the synaptic cleft into the presynaptic cytoplasm.
Inhibition: Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine or sertraline competitively block the substrate translocation pathway of SERT, trapping 5-HT in the cleft. Cocaine and methylphenidate block DAT, elevating synaptic dopamine.
Reversal: Amphetamines act as substrate-mimics, entering the terminal and reversing the direction of transporter flux, causing DAT and SERT to pump monoamines outward into the synapse independently of action potentials.

2. Vesicular Monoamine Transporter 2 (VMAT2 / SLC18A2)

Once monoamines are returned to the presynaptic cytoplasm by SLC6 transporters, they face immediate oxidative deamination by mitochondrial monoamine oxidase (MAO).
To prevent destruction and permit future release, VMAT2 packages cytoplasmic monoamines into acidic storage vesicles, utilizing a proton electrochemical gradient generated by a vacuolar $H^+$-ATPase ($2\text{ }H^+$ pumped out per monoamine pumped in).
The classical antihypertensive reserpine irreversibly inhibits VMAT2, causing total monoamine depletion and severe clinical depression.

3. Endocannabinoid transport and FABP chaperones

Because endocannabinoids are lipophilic lipids, they cannot diffuse freely through the aqueous cytoplasm to reach membrane-bound intracellular degrading enzymes (FAAH and MAGL).
Intracellular transport is mediated by Fatty Acid Binding Proteins—specifically FABP5 and FABP7—alongside heat shock protein 70 (HSP70).
Inhibiting FABPs prevents anandamide from reaching intracellular FAAH, functioning as a non-enzymatic method to elevate synaptic endocannabinoid signaling.

Filed under Substances and pharmacology Organic chemistry and synthesis